Ion Beam Applications SA
Gery Gevers has a diverse work experience spanning several industries. Gery has held various roles at IBA, a medical technology company. Gery started as a Project Manager Assistant in 1998 and worked their way up to Project Manager and then Project Director. In 2006, Gevers became the VP of Project Operations, where they led a team and was responsible for building Proton Therapy Centers. Gery transitioned to VP of Research and Development for Particle Therapy Systems in 2009 and served in that role until 2010. From 2010 to 2016, Gevers held the position of VP of Research and Development for Medical Accelerator Solutions. In 2017, they became an Executive Vice President, first for Software Solutions and then for Digital Solutions. Before joining IBA, Gevers worked as a Project Manager at Desmet Ballestra and as a Project Engineer at IRM Group.
Gery Gevers received a degree in electrician engineering from Université catholique de Louvain in 1992. In 1992-1993, they took elected courses on International Business and Management at Maastricht University. In 2003, they attended INSEAD and completed the Management Acceleration Program, focusing on general management and leadership courses.
This person is not in the org chart
This person is not in any teams
Ion Beam Applications SA
4 followers
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.